Literature DB >> 11394892

Neuroendocrine cells along the digestive tract express neuropilin-2.

T Cohen1, Z Gluzman-Poltorak, A Brodzky, V Meytal, E Sabo, I Misselevich, M Hassoun, J H Boss, M Resnick, D Shneyvas, S Eldar, G Neufeld.   

Abstract

Neuropilin-2 (np-2) is a receptor for semaphorin-3F (sema-3F) and semaphorin-3C (sema-3C). These semaphorins repel tips of growing axons that express np-2. In addition, np-2 functions as a receptor for heparin binding forms of the angiogenic factor vascular endothelial growth factor (VEGF) such as VEGF145 and VEGF165. We report that np-2 is strongly expressed in neuroendocrine cells located all along the human digestive tract. Confocal fluorescent microscopy revealed that np-2 is concentrated in vesicle-like structures located near the nucleus at the basolateral side of these cells. In the colon, the np-2-expressing subpopulation of neuroendocrine cell is almost identical with the serotonin-producing subpopulation of neuroendocrine cells. Gastrointestinal carcinoid tumors are digestive tract tumors that develop from neuroendocrine cells. Interestingly, most of the carcinoid tumors derived from the colon and the appendix did not contain np-2-producing cells. However, some carcinoid tumors derived from the small intestine and stomach did express low levels of np-2 in isolated foci of cells. By contrast, strong serotonin and chromogranin-A expression was observed in all of the carcinoid tumors that were examined. These results suggest that loss of np-2 expression may accompany tumor progression in carcinoid tumors. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11394892     DOI: 10.1006/bbrc.2001.4958

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.

Authors:  Karthikeyan Mythreye; Gerard C Blobe
Journal:  Cell Signal       Date:  2009-05-08       Impact factor: 4.315

Review 2.  Neuropilins: expression and roles in the epithelium.

Authors:  Jonathan R L Wild; Carolyn A Staton; Keith Chapple; Bernard M Corfe
Journal:  Int J Exp Pathol       Date:  2012-04       Impact factor: 1.925

3.  Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis.

Authors:  Seiji Takashima; Masafumi Kitakaze; Masanori Asakura; Hiroshi Asanuma; Shoji Sanada; Fumi Tashiro; Hitoshi Niwa; Jun-ichi Miyazaki Ji; Seiichi Hirota; Yukihiko Kitamura; Takashi Kitsukawa; Hajime Fujisawa; Michael Klagsbrun; Masatsugu Hori
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

Review 4.  Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance.

Authors:  Ridwan Islam; Juhi Mishra; Sanika Bodas; Sreyashi Bhattacharya; Surinder K Batra; Samikshan Dutta; Kaustubh Datta
Journal:  Cancer Metastasis Rev       Date:  2022-07-01       Impact factor: 9.237

5.  Control of CDH1/E-Cadherin Gene Expression and Release of a Soluble Form of E-Cadherin in SARS-CoV-2 Infected Caco-2 Intestinal Cells: Physiopathological Consequences for the Intestinal Forms of COVID-19.

Authors:  Ikram Omar Osman; Clémence Garrec; Gabriel Augusto Pires de Souza; Ana Zarubica; Djamal Brahim Belhaouari; Jean-Pierre Baudoin; Hubert Lepidi; Jean-Louis Mege; Bernard Malissen; Bernard La Scola; Christian Albert Devaux
Journal:  Front Cell Infect Microbiol       Date:  2022-05-04       Impact factor: 6.073

Review 6.  Semaphorin signals on the road to cancer invasion and metastasis.

Authors:  Sabrina Rizzolio; Luca Tamagnone
Journal:  Cell Adh Migr       Date:  2007-04-13       Impact factor: 3.405

7.  The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors.

Authors:  Julien Bollard; Patrick Massoma; Cécile Vercherat; Martine Blanc; Florian Lepinasse; Nicolas Gadot; Christophe Couderc; Gilles Poncet; Thomas Walter; Marie-Odile Joly; Valérie Hervieu; Jean-Yves Scoazec; Colette Roche
Journal:  Oncotarget       Date:  2015-11-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.